Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 921682, 6 pages
http://dx.doi.org/10.1155/2010/921682
Review Article

New Targeted Molecular Therapies for Dedifferentiated Thyroid Cancer

1Department of Internal Medicine, Metabolism Unit, University of Pisa School of Medicine, Via Roma, 67, 56100 Pisa, Italy
2Rheumatology Unit, Department of Internal Medicine, School of Medicine, University of Modena and Reggio Emilia, Via del Pozzo, 71, 41100 Modena, Italy

Received 3 August 2009; Revised 16 January 2010; Accepted 22 March 2010

Academic Editor: Thomas J. Fahey

Copyright © 2010 Alessandro Antonelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. L. Mazzaferri and N. Massoll, “Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin,” Endocrine-Related Cancer, vol. 9, no. 4, pp. 227–247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Schlumberger, “Papillary and follicular thyroid carcinoma,” The New England Journal of Medicine, vol. 338, no. 5, pp. 297–306, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. B. R. Haugen, “Management of the patient with progressive radioiodine non-responsive disease,” Seminars in Surgical Oncology, vol. 16, no. 1, pp. 34–41, 1999. View at Google Scholar · View at Scopus
  4. S. Filetti, J.-M. Bidart, F. Arturi, B. Caillou, D. Russo, and M. Schlumberger, “Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism,” European Journal of Endocrinology, vol. 141, no. 5, pp. 443–457, 1999. View at Google Scholar · View at Scopus
  5. M. Braga-Basaria and M. D. Ringel, “Clinical review 158: beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 1947–1960, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Oler and J. M. Cerutti, “High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes,” Cancer, vol. 115, no. 5, pp. 972–980, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Romei, R. Ciampi, P. Faviana et al., “BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer,” Endocrine-Related Cancer, vol. 15, no. 2, pp. 511–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Riesco-Eizaguirre, I. Rodríguez, A. De La Vieja et al., “The BRAFV600E oncogene induces transforming growth factor ß secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer,” Cancer Research, vol. 69, no. 21, pp. 8317–8325, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. A. Knauf, X. Ma, E. P. Smith et al., “Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation,” Cancer Research, vol. 65, no. 10, pp. 4238–4245, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Fagin, “How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy,” Journal of Endocrinology, vol. 183, no. 2, pp. 249–256, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. D. S. Krause and R. A. Van Etten, “Tyrosine kinases as targets for cancer therapy,” The New England Journal of Medicine, vol. 353, no. 2, pp. 172–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Ouyang, J. A. Knauf, E. P. Smith et al., “Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo,” Clinical Cancer Research, vol. 12, no. 6, pp. 1785–1793, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. D. B. Solit, L. A. Garraway, C. A. Pratilas et al., “BRAF mutation predicts sensitivity to MEK inhibition,” Nature, vol. 439, no. 7074, pp. 358–362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Knauf, H. Kuroda, S. Basu, and J. A. Fagin, “RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase,” Oncogene, vol. 22, no. 28, pp. 4406–4412, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Bounacer, A. McGregor, J. Skinner, J. Bond, Z. Poghosyan, and D. Wynford-Thomas, “Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways,” Oncogene, vol. 23, no. 47, pp. 7839–7845, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Shinohara, J. C. Yun, M. Saji, and M. D. Ringel, “AKT in thyroid tumorigenesis and progression,” Endocrinology, vol. 148, no. 3, pp. 942–947, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Zhu, R. Ciampi, M. N. Nikiforova, M. Gandhi, and Y. E. Nikiforov, “Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3603–3610, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Ciampi, “Nikiforov YE RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis,” Endocrinology, vol. 148, no. 3, pp. 936–941, 2007. View at Google Scholar
  19. Q. De Vita, M. Zannini, A. M. Cirafici et al., “Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors,” Cell Growth and Differentiation, vol. 9, no. 1, pp. 97–103, 1998. View at Google Scholar · View at Scopus
  20. R. M. Melillo, M. D. Castellone, V. Guarino et al., “The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells,” Journal of Clinical Investigation, vol. 115, no. 4, pp. 1068–1081, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Mitsutake, J. A. Knauf, S. Mitsutake, C. Mesa Jr., L. Zhang, and J. A. Fagin, “Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells,” Cancer Research, vol. 65, no. 6, pp. 2465–2473, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Miyagi, M. Braga-Basaria, E. Hardy et al., “Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells,” Molecular Carcinogenesis, vol. 41, no. 2, pp. 98–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. H. S. Jung, D. W. Kim, Y. S. Jo et al., “Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases,” Molecular Endocrinology, vol. 19, no. 11, pp. 2748–2759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. C. S. Mitsiades, J. Negri, C. McMullan et al., “Targeting BRAFV600E in thyroid carcinoma: therapeutic implications,” Molecular Cancer Therapeutics, vol. 6, no. 3, pp. 1070–1078, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Leboeuf, J. E. Baumgartner, M. Benezra et al., “BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 6, pp. 2194–2201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Bunone, P. Vigneri, L. Mariani et al., “Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features,” American Journal of Pathology, vol. 155, no. 6, pp. 1967–1976, 1999. View at Google Scholar · View at Scopus
  27. C. M. Lennard, A. Patel, J. Wilson et al., “Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer,” Surgery, vol. 129, no. 5, pp. 552–558, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. N. G. de la Torre, I. Buley, J. A. H. Wass, and H. E. Turner, “Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour,” Endocrine-Related Cancer, vol. 13, no. 3, pp. 931–944, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Schoenberger, D. Grimm, P. Kossmehl, M. Infanger, E. Kurth, and C. Eilles, “Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study,” Endocrinology, vol. 145, no. 3, pp. 1031–1038, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. N. Younes, Y. D. Yazici, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers, “Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer,” Clinical Cancer Research, vol. 12, no. 11 I, pp. 3425–3434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Ferrara and R. S. Kerbel, “Angiogenesis as a therapeutic target,” Nature, vol. 438, no. 7070, pp. 967–974, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. R. S. Kerbel, “Antiangiogenic therapy: a universal chemosensitization strategy for cancer?” Science, vol. 312, no. 5777, pp. 1171–1175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. D. W. Kim, Y. S. Jo, H. S. Jung et al., “An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4070–4076, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. C. C. Cheung, S. Ezzat, J. L. Freeman, I. B. Rosen, and S. L. Asa, “Immunohistochemical diagnosis of papillary thyroid carcinoma,” Modern Pathology, vol. 14, no. 4, pp. 338–342, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Hoffmann, A. Burchert, A. Wunderlich et al., “Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines,” Endocrine, vol. 31, no. 2, pp. 105–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Carlomagno, D. Vitagliano, T. Guida et al., “ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases,” Cancer Research, vol. 62, no. 24, pp. 7284–7290, 2002. View at Google Scholar · View at Scopus
  37. J. C. Mitchell and S. Parangi, “Angiogenesis in benign and malignant thyroid disease,” Thyroid, vol. 15, no. 6, pp. 494–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Lanzi, G. Cassinelli, G. Cuccuru et al., “Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1,” Cellular and Molecular Life Sciences, vol. 60, no. 7, pp. 1449–1459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Mologni, E. Sala, S. Cazzaniga et al., “Inhibition of RET tyrosine kinase by SU5416,” Journal of Molecular Endocrinology, vol. 37, no. 2, pp. 199–212, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Carlomagno, D. Vitagliano, T. Guida et al., “The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes,” Cancer Research, vol. 62, no. 4, pp. 1077–1082, 2002. View at Google Scholar · View at Scopus
  41. F. Carlomagno, D. Vitagliano, T. Guida et al., “Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2),” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 4, pp. 1897–1902, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. R. S. Herbst, J. V. Heymach, M. S. O'Reilly, A. Onn, and A. J. Ryan, “Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 2, pp. 239–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Kim, Y. D. Yazici, S. E. Barber et al., “Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11,” Head and Neck, vol. 28, no. 5, pp. 389–399, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. D. S. Kim, J. A. Franklyn, K. Boelaert, M. C. Eggo, J. C. Watkinson, and C. J. McCabe, “Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4603–4611, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. C. J. Strock, J.-I. Park, D. M. Rosen et al., “Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 79–84, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Santoro and F. Carlomagno, “Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer,” Nature Clinical Practice Endocrinology and Metabolism, vol. 2, no. 1, pp. 42–52, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Polverino, A. Coxon, C. Starnes et al., “AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts,” Cancer Research, vol. 66, no. 17, pp. 8715–8721, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Carlomagno, S. Anaganti, T. Guida et al., “BAY 43-9006 inhibition of oncogenic RET mutants,” Journal of the National Cancer Institute, vol. 98, no. 5, pp. 326–334, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Vidal, S. Wells, A. Ryan, and R. Cagan, “ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma,” Cancer Research, vol. 65, no. 9, pp. 3538–3541, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Boughton, L. Rosen, A. Van Vugt et al., “Safety and antitumor activity of AMG 706 in patients with thyroid cancer: a subset analysis from a phase I dose-finding study,” Journal of Clinical Oncology, vol. 24, 2006, abstract no. 3030, ASCO Meeting, Atlanta, Ga, USA. View at Google Scholar
  51. S. Kim, L. S. Rosen, E. E. Cohen et al., “A phase II study of axinitib (AG-013736), a potent inhibitor of VE GFRs, in patients with advanced thyroid cancer,” Journal of Clinical Oncology, vol. 24, 2006, abstract no. 5529, ASCO Meeting, Atlanta, Ga, USA. View at Google Scholar
  52. R. Kloos, M. Ringel, M. Knopp et al., “Significant clinical and biological activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study,” Journal of Clinical Oncology, vol. 24, 2006, abstract no. 5534, ASCO Meeting, Atlanta, Ga, USA. View at Google Scholar
  53. E. E. W. Cohen, L. S. Rosen, E. E. Vokes et al., “Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4708–4713, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. I. Sherman, L. J. Wirth, J.-P. Droz et al., “Motesanib diphosphate in progressive differentiated thyroid cancer,” The New England Journal of Medicine, vol. 359, no. 1, pp. 31–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. V. Gupta-Abramson, A. B. Troxel, A. Nellore et al., “Phase II trial of sorafenib in advanced thyroid cancer,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4714–4719, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. R. T. Kloos, M. D. Ringel, M. V. Knopp et al., “Phase II trial of sorafenib in metastatic thyroid cancer,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1675–1684, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Schroyens, E. Tueni, P. Dodion, R. Bodecker, F. Stoessel, and J. Klastersky, “Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer,” European Journal of Cancer, vol. 26, no. 7, pp. 834–838, 1990. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Antonelli, P. Fallahi, S. M. Ferrari et al., “Dedifferentiated thyroid cancer: a therapeutic challenge,” Biomedicine and Pharmacotherapy, vol. 62, no. 8, pp. 559–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration,” European Journal of Endocrinology, vol. 159, no. 3, pp. 283–291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests,” Clinical Endocrinology, vol. 69, no. 1, pp. 148–152, 2008. View at Publisher · View at Google Scholar · View at Scopus